134557-63-4

Basic information

• Product Name: 2-butenoic acid, (1R-{1α[RS(RS(E))],2β})-4-[(2-{[2-(1H-indol-3-yl)-2-methyl-2-({[(2-methylcyclohexyl)oxy]carbonyl}amino)-1-oxopropyl]amino}-1-phenylethyl)amino]-4-oxo-
• Synonyms: 2-butenoic acid, (1R-{1α[RS(RS(E))],2β})-4-[(2-{[2-(1H-indol-3-yl)-2-methyl-2-({[(2-methylcyclohexyl)oxy]carbonyl}amino)-1-oxopropyl]amino}-1-phenylethyl)amino]-4-oxo-
• CAS NO: 134557-63-4
• Molecular Weight: 574.677
• Mol File: 134557-63-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-butenoic acid, (1R-{1α[RS(RS(E))],2β})-4-[(2-{[2-(1H-indol-3-yl)-2-methyl-2-({[(2-methylcyclohexyl)oxy]carbonyl}amino)-1-oxopropyl]amino}-1-phenylethyl)amino]-4-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-butenoic acid, (1R-{1α[RS(RS(E))],2β})-4-[(2-{[2-(1H-indol-3-yl)-2-methyl-2-({[(2-methylcyclohexyl)oxy]carbonyl}amino)-1-oxopropyl]amino}-1-phenylethyl)amino]-4-oxo-(134557-63-4)
• EPA Substance Registry System: 2-butenoic acid, (1R-{1α[RS(RS(E))],2β})-4-[(2-{[2-(1H-indol-3-yl)-2-methyl-2-({[(2-methylcyclohexyl)oxy]carbonyl}amino)-1-oxopropyl]amino}-1-phenylethyl)amino]-4-oxo-(134557-63-4)

Safety Data

• Hazardous Substances Data: 134557-63-4(Hazardous Substances Data)

Upstream product

• 146516-48-5 [(R)-1-((R)-2-Amino-2-phenyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-1-methyl-ethyl]-carbamic acid (1R,2R)-2-methyl-cyclohexyl ester 
• 146566-52-1 (1R-trans)-α-methyl-N-<<(2-methylcyclohexyl)oxy>carbonyl>-(R)-tryptophan 
• 96551-27-8 α-methyl-(R)-tryptophan methyl ester 
• 19043-03-9 (1R,2R)-(-)-trans-2-methylcyclohexanol 
• 134558-17-1 (E)-3-{(R)-2-[(R)-3-(1H-Indol-3-yl)-2-methyl-2-((1R,2R)-2-methyl-cyclohexyloxycarbonylamino)-propionylamino]-1-phenyl-ethylcarbamoyl}-acrylic acid 2-trimethylsilanyl-ethyl ester 

Relevant articles and documents

Cholecystokinin dipeptoid antagonists: Design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and 'mixed' CCK-A/CCK-B antagonists

The design, synthesis, and structure-activity relationships (SAR) for the development of selective dipeptoid ligands for both of the cholecystokinin (CCK) receptor subtypes CCK-A and CCK-B are described. The SAR developed is used to design a ligand with e